Cencora Inc. (COR)vsUBS Group AG (UBS)
COR
Cencora Inc.
$261.08
+2.12%
HEALTHCARE · Cap: $49.74B
UBS
UBS Group AG
$45.23
+1.85%
FINANCIAL SERVICES · Cap: $148.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 541% more annual revenue ($328.68B vs $51.31B). UBS leads profitability with a 17.8% profit margin vs 0.8%. UBS appears more attractively valued with a PEG of 0.53. UBS earns a higher WallStSmart Score of 79/100 (B+).
COR
Buy64
out of 100
Grade: C+
UBS
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.1%
Fair Value
$1266.50
Current Price
$261.08
$1005.42 discount
Intrinsic value data unavailable for UBS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 107 in profit
Earnings expanding 128.3% YoY
Growing faster than its price suggests
Generating 1.2B in free cash flow
Strong operational efficiency at 31.5%
Earnings expanding 84.4% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
3.8% revenue growth
0.8% margin — thin
Operating margin of 1.7%
Trading at 26.6x book value
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, EPS Growth, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bull Case : UBS
The strongest argument for UBS centers on Operating Margin, EPS Growth, Market Cap. Profitability is solid with margins at 17.8% and operating margin at 31.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : COR
The primary concerns for COR are Revenue Growth, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.
Bear Case : UBS
No major red flags identified for UBS, but monitor valuation.
Key Dynamics to Monitor
COR profiles as a value stock while UBS is a mature play — different risk/reward profiles.
UBS carries more volatility with a beta of 0.83 — expect wider price swings.
UBS is growing revenue faster at 13.8% — sustainability is the question.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
UBS scores higher overall (79/100 vs 64/100), backed by strong 17.8% margins and 13.8% revenue growth. COR offers better value entry with a 71.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
UBS Group AG
FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA
UBS Group AG, provides advice and financial solutions to private, institutional and corporate clients worldwide. The company is headquartered in Zurich, Switzerland.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?